Dietary Supplements for the Treatment of Angelman Syndrome

University of California San Diego

Status

Completed

Conditions

Angelman Syndrome

Nervous System Diseases

Treatments

Drug: Betaine

Drug: Metafolin

Drug: Creatine

Drug: Vitamin B12

Study type

Interventional

Funder types

Other

NETWORK

Identifiers

NCT00348933

RDCRN 5204

Details and patient eligibility

About

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.

Full description

AS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is caused by a missing or incomplete chromosome 15 that is inherited from the mother. Diagnosis of AS is usually made between three and seven years of age, when the characteristic behaviors and features of the disease become most evident. Prior to AS diagnosis, the symptoms may be mistaken for cerebral palsy or autism. Physical, occupational, and speech therapy, communication skills development, and behavior modification help to improve the quality of life of these children, but other treatments are needed.

In a previous study, decreased DNA methylation, which is a type of chemical change in DNA, was observed in an individual with AS; this condition may be a primary cause of AS. It is hypothesized that promoting increased DNA methylation might reduce the severity of AS symptoms. Betaine, creatine, Metafolin, and vitamin B12 are compounds normally found in the body that are involved in the DNA methylation pathway. Increasing the concentrations of these compounds in the body may enhance DNA methylation. This study will evaluate the efficacy of four dietary supplements in treating the symptoms of AS.

This study will last 12 months. Study visits will occur at study entry and Month 12. A selected group of participants, those who meet the diagnostic criteria for autism, will also be evaluated at Month 6. At study visits, participants will undergo an electroencephalogram (EEG). Medical history, physical exam, neurological exams, and developmental assessments will also be performed. Urine and blood collection, including tests to determine the blood levels of the dietary supplements, will occur at study entry and Months 6 and 12. Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for the duration of the study. Parents will be asked to complete a questionnaire at each visit to report their child's behavior while taking the dietary supplements. Parents will also be contacted by phone periodically to assess changes and/or progress in their children.

Enrollment

90 patients

Sex

All

Ages

1 day to 5 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of AS
In stable condition with relatively good control of seizures
Willing to comply with treatment, study visit schedule, and study assessments
Willing to take oral or G-tube medication
Willing to be contacted monthly during the course of the study
Parent or guardian willing to provide informed consent

Exclusion criteria

History of liver or kidney disease
Currently being treated for a serious acute illness
Known hypersensitivity to any of the study drugs
Received high-dose folate drug treatment in the 12 months prior to study entry
Other significant medical problems, including those involving the liver, kidney, or heart
Other comorbidities, genetic disorders, or extreme prematurity; children with autism are not excluded